Table 2 Mutation status in ET and transformed AML cells.

From: Initiating-clone analysis in patients with acute myeloid leukemia secondary to essential thrombocythemia

UPN

Mutation

VAF (%)

ET

AML

1

CALRK385fs*47

ASXL1G643fs

TP53C238S

U2AF1Q157R

22.8

5.1

-

-

34.2

4.7

37.4

33.2

2

CALRL367fs*43

MPLS505N

TP53C153Y

NRASQ61K

51.0

39.0

3.0

-

47.0

45.0

93.0

2.0

3

MPLW515L

TP53R248Q

EZH2G660R

PHF6G306E

75.1

14.1

18.1

27.8

88.0

83.9

40.1

-

4

JAK2V617F

TP53H178P

18.4

-

95.7

96.7

5

JAK2V617F

TET2Q1030*

TET2C1271fs

ASXL1E773*

RUNX1L98fs

CEBPAP23fs

32.5

40.3

36.0

37.3

-

-

50.1

49.6

47.6

53.1

46.6

40.8

6

JAK2V617F

TET2Q278*

TP53M133K

IDH2R140Q

NRASG12S

68.5

10.3

-

-

-

-

48.3

82.4

45.5

6.4

7

JAK2V617F

TET2R1262L

TET2H1380Y

TP53R280S

SRSF2P95R

CBLG413D

84.0

41.8

43.4

-

-

-

9.9

60.0

34.2

77.6

73.8

67.1

8

JAK2V617F

TP53R248W

TP53V173L

SMARCC2D381E

UBR4R450H

ZNF143S286R

40.5

4.7

4.4

50.7

47.7

47.9

2.7

87.5

3.5

47.9

48.5

60.6

  1. - indicates not detected